3 Under the Radar Pharmaceutical Stocks to Add to Your Watchlist

NASDAQ: CPRX | Catalyst Pharmaceuticals, Inc. News, Ratings, and Charts

CPRX – The pharmaceutical industry is expected to attract significant investor attention in the coming months as the demand for vaccines and therapies continues to soar with the resurgence of COVID-19 cases globally. This demand, coupled with an astonishing level of scientific advances for treating several critical diseases, will likely bolster the industry’s growth. Therefore, we believe that under-the-radar pharmaceutical stocks Catalyst Pharmaceuticals (CPRX), Kamada (KMDA), and Opiant Pharmaceuticals (OPNT) could deliver excellent returns in the near term. Let’s discuss.

With the resurgence of COVID-19 cases worldwide, fueled by the rapid spread of the virus’ Delta variant, the pharmaceutical industry is again in the spotlight. This, along with the growing need for personalized therapies and the treatment of rare diseases, has significantly improved the industry’s growth prospects. Investors’ interest in pharmaceutical stocks is evidenced by the Invesco Dynamic Pharmaceuticals ETF’s (PJP) 15.1% returns year-to-date. 

Also, the growing use of advanced technologies and artificial intelligence to accelerate drug discovery and provide life-transforming treatments should further propel the industry’s growth. Consequently, the global pharmaceuticals market is expected to hit  $1,700.97 billion in 2025, growing at an 18%  CAGR.

Therefore, we think under-the-radar pharmaceutical stocks Catalyst Pharmaceuticals, Inc. (CPRX), Kamada Ltd. (KMDA), and Opiant Pharmaceuticals, Inc. (OPNT), which have increased their R&D spending significantly, are well-positioned to continue rallying. Hence, it could be wise to bet on these stocks now.

Click here to checkout our Healthcare Sector Report for 2021

Catalyst Pharmaceuticals, Inc. (CPRX)

A commercial-stage biopharmaceutical company, CPRX in Coral Gables, Fla., provides novel, safe, and efficient therapies to patients with chronic neuromuscular and neurological diseases. The company is developing Firdapse to treat patients with the lambert-eaton myasthenic syndrome (LEMS). In addition, it has collaborations with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.

In July, the United States Patent and Trademark Office (USPTO) issued a new U.S patent to CPRX for Firdapse Tablets 10mg. This new patent should further enhance its intellectual property protection for Firdapse and help it strengthen its brand.

In June, CPRX entered  an exclusive license and supply agreement with DyDo Pharma, Inc. to develop and commercialize Firdapse Tablets 10mg in Japan to treat LEMS. This collaboration should  allow CPRX to address the unmet medical needs of its patients and grow its sales milestones for Firdapse.

During the second quarter, ended June 30, 2021, CPRX’s total revenues increased 23% year-over-year to $36.4 million. Its Firdapse product revenue grew 14% from the prior-year quarter to $33.6 million. Also, the company’s operating income increased 54% year-over-year to $15.84 million. CPRX’s net income increased 24.6% year-over-year to $12.18 million.

Analysts expect CPRX’s revenue for its fiscal year 2021 to be $134.8 million, representing 13.20% year-over-year growth. CPRX has an impressive earnings surprise history; it beat the consensus EPS estimates in three of the trailing four quarters. The company’s EPS is expected to increase 10.30% for the next year. Also, the stock has surged 67.4% in price over the past year and 38.7% over the past six months.

CPRX’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall B rating, which equates to Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

CPRX has a Value grade of A, and a Quality grade of B. Within the Medical-Pharmaceuticals industry, it is ranked #32 of 215 stocks. In addition, we have graded CPRX for Momentum, Growth, Sentiment, and Stability. Click here to access all CPRX’s ratings.

Kamada Ltd. (KMDA)

Based in Rehovot, Israel, KMDA offers specialty plasma-derived protein therapeutics. It operates through Proprietary Products and Distribution segments. The company markets its products through strategic partners in the U.S as well as through distributors internationally. KMDA has partnerships with Takeda Pharmaceutical Company Ltd., PARI GmbH, and Kedrion Biopharma.

In June, KMDA and Kedrion announced the FDA’s approval of KEDRAB, the first and only human rabies immune globulin (HRIG). KMDA believes that this approval will support the increase of KEDRAB’s market share in the United States. It could also help the company capture a notable portion of the estimated annual $150 million U.S. HRIG product market.

KMDA’s cash and cash equivalent increased 19.2% year-over-year to $68.42 million in the second quarter, ended June 30, 2021. Its total revenues stood at $24.2 million, while its gross profit came in at $9.1 million. Also, the company’s adjusted EBITDA totaled $2.4 million, while its net income stood at $0.9 million for the quarter.

The company’s EPS is expected to increase 20% year-over-year to $0.12 next year.

KMDA’s POWR Ratings reflect this promising outlook. The company has an overall B rating, which translates to Buy in our proprietary ratings system. KMDA is also rated an A in Value, and a B in Stability. In the same industry, it is ranked #24.

To see additional POWR Ratings for Sentiment, Momentum, Quality, and Growth for KMDA, click here.

Opiant Pharmaceuticals, Inc. (OPNT)

OPNT, which is based in Santa Monica, Calif., is a specialty pharmaceutical company that produces medicines for addiction and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdose. In addition, it provides medicines for the treatment of alcohol use disorder, acute cannabinoid overdose, and opioid use disorders.

In July, the company announced positive top-line results from its confirmatory pharmacokinetic study for OPNT003 to treat opioid overdose. The study is consistent with the findings of OPNT’s initial pilot study and demonstrates the company’s efforts to reduce the number of opioid overdose deaths.

In the second quarter, ended June 30, 2021, OPNT’s revenue increased 79.4% year-over-year to $11.3 million, driven primarily by NARCAN Nasal Spray royalties. Its net income came in at $1.68 million, versus  a $0.22 million net loss in the second quarter of 2020. The company’s EPS came in at $0.31, compared to a $0.05 loss per share in the prior-year period.

OPNT’s revenue for its fiscal year 2021 is estimated to be $37 million, indicating a 24.9% improvement year-over-year. The company has an impressive earnings surprise history; it beat the consensus EPS estimates in three of the trailing four quarters. OPNT’s stock has gained 86% in price over the past nine months and 90.2% year-to-date.

It is no surprise that OPNT has an A grade for Sentiment, and a B for Value. In the same industry, it is ranked #34.

In total, we rate OPNT on eight different levels. Beyond what we’ve stated above, we have also given OPNT grades for Growth, Quality, Momentum, and Stability. Get all the OPNT ratings here.

Click here to checkout our Healthcare Sector Report for 2021

CPRX shares were trading at $5.58 per share on Wednesday morning, down $0.01 (-0.18%). Year-to-date, CPRX has gained 67.07%, versus a 20.69% rise in the benchmark S&P 500 index during the same period.

About the Author: Imon Ghosh

Imon is an investment analyst and journalist with an enthusiasm for financial research and writing. She began her career at Kantar IMRB, a leading market research and consumer consulting organization. More...

More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CPRXGet RatingGet RatingGet Rating
KMDAGet RatingGet RatingGet Rating
OPNTGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com

Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

3 Auto Stocks to Consider Over TSLA in April

Tesla (TSLA) reported a decline in deliveries in the first quarter, and Wall Street expects the company to deliver fewer vehicles than last year. Furthermore, rising competition, slowing EV sales, and stretched valuation make TSLA unattractive from an investment standpoint. Considering these factors, investors could consider buying fundamentally strong auto stocks Blue Bird (BLBD), Rolls-Royce Holdings (RYCEY), and Stellantis (STLA) over Tesla (TSLA). Read more...

3 Top-Rated Tech Stock Buys for Value in April

The technology sector is undergoing a notable surge, propelled by increasing digitalization endeavors among businesses and governmental support for technological progress. So, fundamentally sound tech stocks Box Inc. (BOX), Teradata (TDC), and Materialise (MTLS), which seem pretty undervalued, might be ideal buys this month. Continue reading...

Top Software Stocks at the Forefront of Market Gains

The software industry's prospects appear bright due to increasing investments in digital transformation, high demand for advanced software services from various sectors, and the integration of emerging technologies such as generative AI. Therefore, investors could consider buying quality software stocks Autodesk (ADSK), DocuSign (DOCU), and Pegasystems (PEGA) for solid gains. Read more...

Does the Stock Market Have Indigestion?

The easy gains have already rolled in for the S&P 500 (SPY) to new heights. However, signs point to stocks entering a stage of “digestion”. What does that mean? And what does it tell us about investing in stocks the rest of the year? Steve Reitmeister shares his time views in this new market commentary including a preview of this top stocks to outperform. Get the full story below...

Read More Stories

More Catalyst Pharmaceuticals, Inc. (CPRX) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CPRX News